MedPath

Hemabate

Hemabate carboprost tromethamine injection, USP

Approved
Approval ID

3d282998-ff0c-480a-bd80-155606ef0a65

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 10, 2022

Manufacturers
FDA

Pharmacia & Upjohn Company LLC

DUNS: 618054084

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

carboprost tromethamine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0009-0856
Application NumberNDA017989
Product Classification
M
Marketing Category
C73594
G
Generic Name
carboprost tromethamine
Product Specifications
Route of AdministrationINTRAMUSCULAR
Effective DateJanuary 10, 2022
FDA Product Classification

INGREDIENTS (6)

CARBOPROST TROMETHAMINEActive
Quantity: 250 ug in 1 mL
Code: U4526F86FJ
Classification: ACTIM
TROMETHAMINEInactive
Quantity: 83 ug in 1 mL
Code: 023C2WHX2V
Classification: IACT
SODIUM CHLORIDEInactive
Quantity: 9 mg in 1 mL
Code: 451W47IQ8X
Classification: IACT
BENZYL ALCOHOLInactive
Quantity: 9.45 mg in 1 mL
Code: LKG8494WBH
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Hemabate - FDA Drug Approval Details